Due to the prodigious response to our press release regarding the Prostate Screening EpiSwitch® (PSE), we wanted to give everyone a quick update. Currently, the PSE is not commercially available, and no clinical trials are underway. We are working hard to bring this important test into the clinical lab for routine diagnostic testing. For more information regarding the PSE, please check out our press release and published article in Cancers. Thank you for being so supportive, and please check our website for future updates on this subject.
ServiceEpiSwitch® Services are offered to accelerate development of biomarker and companion diagnostics for biotech and pharmaceutical partners
Latest Example of EpiSwitch® Biomarker Services in Immuno-Oncology for our US Clients
View PublicationsThe purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform. Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats for added versatility.
We require 2 µg high quality genomic DNA. Additional QC will be performed in-house prior to array processing.
We send images (.tif), QC reports (.pdf) and full data (.txt) securely to you via the NextCloud file sharing platform.
*Required fields